BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:03 PM
May 24, 2010
 |  BC Extra  |  Top Story

Lucentis meets DME endpoint

Novartis AG (NYSE:NVS; SIX:NOVN) said 0.5 mg intravitreal Lucentis ranibizumab with and without laser therapy met the primary endpoint in the Phase III RESTORE trial to treat diabetic macular edema (DME). Both Lucentis groups significantly improved best-corrected visual acuity (BCVA) score from baseline to 12 months vs....

Read the full 221 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >